Roger Robertson, DO
Urology · Huntington, WVNPI 1275823544
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,796 of the $2,732 with a category attached, or 65.7%. 22 manufacturers reported payments, led by Coloplast at 38.2% of the total. Reporting peaked in 2019 at $1,234 and has fallen 89.1% since, to $134 in 2025.
Across 119 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Astellas Pharma US Inc$318
- Pfizer$181
- Medtronic$154
- Endo Pharmaceuticals Inc.$154
- AbbVie$135
- plus $747 from 16 others
What the payments were for
- Travel & lodging$44316%
- Food & beverage$1,79666%
- Education$49318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 20 | $1,043 |
| Astellas Pharma US Inc | 18 | $318 |
| Pfizer | 11 | $181 |
| Medtronic | 6 | $154 |
| Endo Pharmaceuticals Inc. | 9 | $154 |
| AbbVie(2 entities) | 10 | $135 |
| Axonics, Inc. | 6 | $88 |
| Myriad Genetic Laboratories, Inc. | 4 | $83 |
| Boston Scientific | 5 | $72 |
| Halozyme Inc | 3 | $70 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Myovant Sciences Inc. | 3 | $51 |
| Procept Biorobotics Corporation | 2 | $51 |
| Conmed Corporation | 1 | $49 |
| Bayer | 3 | $44 |
| Antares Pharma, Inc. | 1 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Travere Therapeutics, Inc. | 7 | $32 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Urogen Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,732 in reported general payments places this provider in the 55th percentile of 67 urology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 54 | $50,316 |
| Oxybutynin Chloride ErOxybutynin Chloride | 454 | $12,534 |
| Tamsulosin Hcl | 755 | $10,212 |
| Finasteride | 466 | $6,260 |
| Trimethoprim | 67 | $4,611 |
| Estradiol | 52 | $3,406 |
| NitrofurantoinNitrofurantoin Macrocrystal | 71 | $2,900 |
| Solifenacin Succinate | 51 | $2,176 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $2,163 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,410 |
| Testosterone Cypionate | 25 | $1,039 |
| Cephalexin | 106 | $883 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 54 | $794 |
| CefuroximeCefuroxime Axetil | 41 | $558 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $318 | $50,31654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 67 urology providers in West Virginia.
Other urology in Huntington
- Stanley ZaslauHuntington$14K
- Rocco MorabitoHuntington$6K
- Amjad AlwaalHuntington$5K
- Margaret VerebHuntington$4K
- James JensenHuntington$4K
- Frederick MartinezHuntington$3K
- Justyn BlankenshipHuntington$3K
- Rocco MorabitoHuntington$3K
- Lawrence WynerHuntington$2K
- Mark ThomasHuntington$787
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.